This is the logo of the provider
ADA 2025 20 - 23 June 2025

Oral Semaglutide and Cardiovascular Outcomes by Baseline A1c and BMI in People with Type 2 Diabetes in the SOUL Trial

Authors :

Silvio E. Inzucchi1; Rohana Abdul Ghani2; John Deanfield3; Mads D. M. Engelmann4; G. Kees Hovingh4; Ole K. Jeppesen4; Monika Kellerer5; Kabirdev Mandavya6; Johannes F. Mann7; Nikolaus Marx8; Chantal Mathieu9; Darren K. McGuire10; Viswanathan Mohan11; Sharon L. Mulvagh12; Rodica Pop-Busui13; Neil R. Poulter14; Maria Sejersten Ripa4; Gabriela Roman15; Róbinson Sánchez García16; Michael Shechter17; John B. Buse18on behalf of the SOUL Study Group

Affiliations
View Details Hide Details
This is the logo of the provider
{{ getPageNum(PDFPage) }}
Keywords
Diabetes
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)